Answers are grounded in this paper and cite their sources.
State-of-the-art review shows improved diagnostic imaging and treatment options for CTEPH, suggesting better outcomes.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, chronic, progressive, and life-limiting condition with a poor five-year survival in untreated patients with advanced disease. Multi-modality imaging techniques are used in making the diagnosis and determining treatment options in CTEPH. Pulmonary endarterectomy (PEA) surgery is the treatment of choice in selected patients, providing excellent long-term survival. Balloon pulmonary angioplasty (BPA) is an established intervention for selected patients who are not suitable for surgery. Riociguat, a soluble guanylate cyclase stimulator, is a vasodilator and indicated in patients with inoperable disease. In this state-of-the-art review, we provide an update in the diagnostic evaluation with a focus on imaging modalities, treatment strategies, and future directions in CTEPH.
No takes yet. Share an insight, caveat, or question.
Forward et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: